Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13100656 | 0.94 | MTNR1A (0.49) | MTNR1AMTNR1BTAAR1CYP1A2L3MBTL1 | |
| SCHEMBL6667447 | 0.90 | AKR1C3 (0.50) | MTNR1AMTNR1BTAAR1AKR1C3AKR1C2 | |
| SCHEMBL10596068 | 0.87 | AKR1C3 (0.49) | MTNR1AMTNR1BTAAR1AKR1C3AKR1C2 | |
| SCHEMBL5077290 | 0.86 | MTNR1A (0.53) | MTNR1AMTNR1BHDAC1HDAC6 | |
| SCHEMBL6699024 | 0.85 | MTNR1A (0.44) | MTNR1AMTNR1BAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL28188563 | 0.84 | AKR1C3 (0.55) | MTNR1AMTNR1BAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL28269690 | 0.83 | MTNR1A (0.51) | MTNR1AMTNR1BAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL28269689 | 0.83 | MTNR1A (0.51) | MTNR1AMTNR1BAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL7041441 | 0.83 | MTNR1A (0.61) | MTNR1AMTNR1BAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL11820853 | 0.83 | ABCB1 (0.51) | MTNR1AMTNR1BAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105541-B2 | Naphthyl compounds, intermediates, compositions, and methods of use | ELI LILLY AND COMPANY (US) | 2006-09-12 | — | — | US | disclosed |
| US-20050054632-A1 | Naphthyl compounds, intermediates, compositions, and methods of use | BRYANT HENRY UHLMAN (US) | 2005-03-10 | — | — | US | disclosed |
| US-6812244-B2 | POSTMENOPAUSAL OSTEOPOROSIS | ELI LILLY AND COMPANY | 2004-11-02 | — | — | US | disclosed |
| US-20040072820-A1 | Naphthyl compounds, intermediates, compositions, and methods of use | BRYANT HENRY UHLMAN (US) | 2004-04-15 | — | — | US | disclosed |
| US-6593345-B1 | Inhibiting bone loss or bone resorption comprising administering to a patient in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt or solvate, and anticholesterol agents | ELI LILLY AND COMPANY | 2003-07-15 | — | — | US | disclosed |
| EP-0826679-B1 | Naphthyl compounds and compositions | LILLY CO ELI (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-1142862-A2 | Naphthyl and tetralone derivatives as intermediates | ELI LILLY AND COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-1998008797-A1 | NAPHTHYL COMPOUNDS, INTERMEDIATES, COMPOSITIONS, AND METHODS OF USE | ELI LILLY AND COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| EP-0826679-A2 | Naphthyl compounds, intermediates, compositions, and method of use | ELI LILLY AND COMPANY (US) | 1998-03-04 | — | — | EP | disclosed |
| US-5021414-A | Antiestrogen | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-06-04 | — | — | US | disclosed |
| US-4904661-A | ANTIESTROGENS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-02-27 | — | — | US | disclosed |
| US-4732912-A | ANTIESTROGENS, ANTITUMOR AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-03-22 | — | — | US | disclosed |
| EP-0124369-B1 | PHENOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-06-24 | — | — | EP | disclosed |
| EP-0124369-A1 | Phenol derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072820-A1 | Naphthyl compounds, intermediates, compositions, and methods of use | SQLE, NQO1, CYP3A43 | MTNR1A 934/4885MTNR1B 796/4885TAAR1 3862/4885 |
| US-20050054632-A1 | Naphthyl compounds, intermediates, compositions, and methods of use | SQLE, NQO1, CYP3A43 | MTNR1A 934/4885MTNR1B 796/4885TAAR1 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.